CENTESSA PHARMACEUTICALS PLC (CNTA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$40.500.00%
Close 2026-06-25 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Centessa completed acquisition by Eli Lilly, becoming a wholly owned subsidiary. The company repaid all debt and liabilities, improving its balance sheet. Analysts expect EPS losses to narrow slightly from -$0.39 next quarter to -$1.56 for FY26. The acquisition could unlock value and operational stability.
Centessa remains loss-making with EPS of -$0.39 next quarter and -$1.56 for FY26. Multiple CEO departures and delisting from Nasdaq raise governance and liquidity concerns. No revenue is currently expected, and analyst EPS estimates decline further for FY27 to -$1.78.
The market currently prices Centessa as a loss-making biotech with no revenue and ongoing negative EPS through FY27. The acquisition by Eli Lilly is known but the market remains cautious on near-term profitability and governance risks.
Breaks if: New debt issuance or financial distress reported
Breaks if: EPS loss worsens beyond -1.56 USD per share in FY26
Additional CEO or multiple senior executive departures occur
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround opportunity in the healthcare sector. The company has recently undergone significant changes, including an acquisition by Eli Lilly and a CEO transition, but it remains loss-making with volatile management.
The market currently reflects low confidence in CNTA, given its weak recent financial performance and ongoing cash burn. Investors seem to expect continued challenges, especially with the potential for further earnings misses.
Fundamentals are likely to remain weak in the near term, with ongoing cash burn and a high probability of missing earnings expectations. The company is managing its operations with cash expected to last into mid-2027, but the trajectory shows continued losses.
The thesis hinges on several factors, including the company's ability to meet or exceed guidance in upcoming earnings calls and the overall health of the healthcare sector. Additionally, performance from sector leaders could influence sentiment around CNTA.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
In the next 1 to 3 years, CNTA faces significant challenges but also potential sector support. Monitoring upcoming earnings and sector performance will be crucial. Not investment advice.